Antibody-drug conjugates (ADCs) and bispecific antibodies were the stars of the recent American Society of Clinical Oncology (ASCO) meeting, where Chinese companies had a major presence this year and accounted for close to half of all the presentations across the two modalities at the 30 May-3 June event in Chicago.
Innovent Biologics was one of the major Chinese firms showcasing its assets, including IBI363, a first-in-class anti-PD-1/IL-2α-bias bispecific which, if...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?